JP2017506074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506074A5 JP2017506074A5 JP2016550266A JP2016550266A JP2017506074A5 JP 2017506074 A5 JP2017506074 A5 JP 2017506074A5 JP 2016550266 A JP2016550266 A JP 2016550266A JP 2016550266 A JP2016550266 A JP 2016550266A JP 2017506074 A5 JP2017506074 A5 JP 2017506074A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- seq
- aptamer according
- sequence
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091023037 Aptamer Proteins 0.000 claims 26
- -1 metapyril Chemical compound 0.000 claims 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 4
- 229960004857 mitomycin Drugs 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229930192392 Mitomycin Natural products 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229960001156 mitoxantrone Drugs 0.000 claims 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 claims 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 229960000640 dactinomycin Drugs 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 claims 2
- 229960000286 proflavine Drugs 0.000 claims 2
- 108010042747 stallimycin Proteins 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims 1
- 108091027757 Deoxyribozyme Proteins 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
- HCOLPNRPCMFHOH-UHFFFAOYSA-N Prodigiosin Natural products CCCCCC1C=C(C=C/2N=C(C=C2OC)c3ccc[nH]3)N=C1C HCOLPNRPCMFHOH-UHFFFAOYSA-N 0.000 claims 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 229960001441 aminoacridine Drugs 0.000 claims 1
- 229960002550 amrubicin Drugs 0.000 claims 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 1
- 229960001220 amsacrine Drugs 0.000 claims 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims 1
- 229940093265 berberine Drugs 0.000 claims 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960003291 chlorphenamine Drugs 0.000 claims 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims 1
- 229960005542 ethidium bromide Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000009830 intercalation Methods 0.000 claims 1
- 230000002687 intercalation Effects 0.000 claims 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001221 pirarubicin Drugs 0.000 claims 1
- 150000003057 platinum Chemical class 0.000 claims 1
- 229960003171 plicamycin Drugs 0.000 claims 1
- TWFGRJUTAULJPZ-USZBIXTISA-N prodigiosin Chemical compound N1=C(C)C(CCCCC)=C\C1=C/C1=NC(C=2[N]C=CC=2)=C[C]1OC TWFGRJUTAULJPZ-USZBIXTISA-N 0.000 claims 1
- 239000002719 pyrimidine nucleotide Substances 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 229960000641 zorubicin Drugs 0.000 claims 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014900347 | 2014-02-05 | ||
| AU2014900347A AU2014900347A0 (en) | 2014-02-05 | Aptamer Construct | |
| PCT/AU2015/050039 WO2015117201A1 (en) | 2014-02-05 | 2015-02-05 | Aptamer construct |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506074A JP2017506074A (ja) | 2017-03-02 |
| JP2017506074A5 true JP2017506074A5 (enExample) | 2018-03-15 |
| JP6636436B2 JP6636436B2 (ja) | 2020-01-29 |
Family
ID=53777070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550266A Active JP6636436B2 (ja) | 2014-02-05 | 2015-02-05 | アプタマー構築体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10221420B2 (enExample) |
| EP (1) | EP3102708B1 (enExample) |
| JP (1) | JP6636436B2 (enExample) |
| CN (1) | CN106164293B (enExample) |
| AR (1) | AR099303A1 (enExample) |
| AU (1) | AU2015213483B2 (enExample) |
| CA (1) | CA2938776C (enExample) |
| ES (1) | ES2851924T3 (enExample) |
| SG (1) | SG11201606379UA (enExample) |
| WO (1) | WO2015117201A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150233932A1 (en) * | 2013-02-19 | 2015-08-20 | Ching-Ping Tseng | Methods, Systems, and Compositions for Enrichment of Rare Cells |
| US11008575B2 (en) * | 2015-07-28 | 2021-05-18 | The University Of North Carolina At Charlotte | DNA aptamers against cancer and uses thereof in delivery of therapy and diagnosis of cancer |
| US11845938B2 (en) | 2016-03-31 | 2023-12-19 | City Of Hope | Aptamer compositions and the use thereof |
| CN105925687A (zh) * | 2016-05-15 | 2016-09-07 | 陈博 | 一种用于儿科的肺吸虫病诊断的试剂盒及其诊断方法 |
| EP3332812A1 (en) * | 2016-12-07 | 2018-06-13 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nucleic acid-based assembly and use of the assembly in cancer therapy |
| CA3062250A1 (en) * | 2017-05-08 | 2018-11-15 | Augmanity Nano Ltd | Treatment of rapidly evolving biological entities |
| CN108866061A (zh) * | 2018-06-21 | 2018-11-23 | 中山大学附属第五医院 | 一种识别肝癌细胞的核酸适配体及其筛选方法与用途 |
| JP7640457B2 (ja) * | 2018-09-28 | 2025-03-05 | オーグマニティ ナノ リミテッド | 機能性アプタマーを選択するための方法および組成物 |
| CN109439665B (zh) * | 2018-12-06 | 2021-04-02 | 浙江省肿瘤医院 | 一种靶向结合cd133蛋白的核酸适配体药物偶联物及其用途 |
| CN109536503B (zh) * | 2018-12-06 | 2021-03-02 | 浙江省肿瘤医院 | 一种靶向结合cd133蛋白的核酸适配体及其筛选方法和用途 |
| CN109536505B (zh) * | 2018-12-07 | 2021-11-09 | 暨南大学 | 鬼臼毒素的核酸适配体及其应用 |
| KR102154683B1 (ko) * | 2019-11-08 | 2020-09-11 | 주식회사 압타머사이언스 | 글리피칸-3 특이적 변형 압타머 및 이의 용도 |
| CN110904112B (zh) * | 2019-12-12 | 2024-04-02 | 福州市长乐区宝爱冬医学技术有限公司 | 一种白喉毒素的核酸适配体dt03及其应用 |
| CN110885828B (zh) * | 2019-12-12 | 2024-04-05 | 方斌 | 一种白喉毒素的核酸适配体dt01及其应用 |
| CN111505287B (zh) * | 2020-05-07 | 2023-04-07 | 军事科学院军事医学研究院军事兽医研究所 | 以乙醛脱氢酶作为信号转导系统检测食源性病原菌的生物传感器及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
| US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
| US6127119A (en) | 1990-06-11 | 2000-10-03 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
| US6028186A (en) | 1991-06-10 | 2000-02-22 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
| AU2486100A (en) | 1998-12-23 | 2000-07-12 | Admetric Biochem Inc. | High throughput method for measuring physicochemical values |
| US6171795B1 (en) | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
| US20050119198A1 (en) | 2002-02-08 | 2005-06-02 | Peter Carmeliet | Novel target to inhibit angiogenesis |
| GB0305422D0 (en) | 2003-03-10 | 2003-04-16 | Univ Open | Detection, monitoring and treatment of cancer |
| US20060263336A1 (en) | 2003-03-24 | 2006-11-23 | Caplan Arnold I | Cell targeting methods and compositions |
| EP1784501B1 (en) | 2004-05-14 | 2015-11-18 | Rosetta Genomics Ltd | VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF |
| US7602495B2 (en) | 2004-08-24 | 2009-10-13 | Fujifilm Corporation | Method for measuring dissociation constant by surface plasmon resonance analysis |
| CA2579374A1 (en) | 2004-09-07 | 2006-03-30 | Archemix Corp. | Aptamers to von willebrand factor and their use as thrombotic disease therapeutics |
| CA2629330C (en) | 2004-11-12 | 2018-05-22 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
| KR101584468B1 (ko) * | 2006-03-08 | 2016-01-13 | 아케믹스 엘엘씨 | 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제 |
| WO2007137117A2 (en) * | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
| JP2007319153A (ja) | 2006-06-02 | 2007-12-13 | Takashi Otsu | 核酸リガンドと中和剤との組み合わせ製剤 |
| WO2009009739A2 (en) | 2007-07-12 | 2009-01-15 | Theracrine, Inc. | Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer |
| US20110206614A1 (en) | 2007-11-23 | 2011-08-25 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
| US20120045846A1 (en) | 2010-08-23 | 2012-02-23 | Avia Biosystems, Llc | SYSTEM AND METHOD FOR pH FORMULATIONS |
| ES2741949T3 (es) | 2012-08-02 | 2020-02-12 | Univ Deakin | Aptámeros CD133 para la detección de células madre cancerosas |
-
2015
- 2015-02-05 JP JP2016550266A patent/JP6636436B2/ja active Active
- 2015-02-05 CA CA2938776A patent/CA2938776C/en active Active
- 2015-02-05 AU AU2015213483A patent/AU2015213483B2/en active Active
- 2015-02-05 SG SG11201606379UA patent/SG11201606379UA/en unknown
- 2015-02-05 WO PCT/AU2015/050039 patent/WO2015117201A1/en not_active Ceased
- 2015-02-05 US US15/117,164 patent/US10221420B2/en active Active
- 2015-02-05 ES ES15747052T patent/ES2851924T3/es active Active
- 2015-02-05 EP EP15747052.7A patent/EP3102708B1/en not_active Not-in-force
- 2015-02-05 CN CN201580011915.5A patent/CN106164293B/zh not_active Expired - Fee Related
- 2015-02-06 AR ARP150100345A patent/AR099303A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506074A5 (enExample) | ||
| Kim et al. | Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy | |
| US11981723B2 (en) | Method of targeting exosomes | |
| Han et al. | Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy | |
| ES2536996T3 (es) | Anticuerpos biespecíficos de unión a digoxigenina | |
| JP6636436B2 (ja) | アプタマー構築体 | |
| AR064360A1 (es) | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos | |
| EP2976109B1 (en) | Cellular delivery of dna intercalating agents | |
| RU2015143208A (ru) | Высокоаффинные антитела kgd2 | |
| WO2010009124A3 (en) | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | |
| JP2015500328A5 (enExample) | ||
| CN110559445B (zh) | 一种靶向载药体系 | |
| KR102023839B1 (ko) | 분지된 dna, 압타머를 포함하는 고효율 압타머 복합체 및 이의 용도 | |
| JP7094893B2 (ja) | エンドシアリン結合抗体 | |
| US20200289613A1 (en) | Methods of treating metastatic cancers using axl decoy receptors | |
| KR20180118716A (ko) | Ｄｂａｉｔ 분자의 전신 투여에 의한 암 치료법 | |
| JP2018506284A5 (enExample) | ||
| JP2016526009A (ja) | 肝細胞癌の検出および治療のための組成物および方法 | |
| KR20190117681A (ko) | Her3 및 cd3에 결합하는 이중특이적 항체 | |
| Rueda et al. | Targeting the chemokine receptor CXCR4 for cancer therapies | |
| JP2017517260A (ja) | Ｍａｇｅ−ａ３ペプチド標的アプタマー及びその使用 | |
| Li et al. | Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer | |
| Joshi et al. | Combination of doxorubicin with gemcitabine-incorporated GQuadruplex aptamer showed synergistic and selective anticancer effect in breast cancer cells | |
| Ianniello et al. | Harnessing ExDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach | |
| TWI631958B (zh) | 抗tmcc3免疫共軛物及其用途 |